Video Shorts

1:22

Kidney Cancer Abstracts to Watch at ASCO GU 2026

6 months ago

Jad Chahoud, MD, MPH, MHA

Malin Hultcrantz, MD, PhD, discusses FDA draft guidance on MRD end points in multiple myeloma clinical trials.

1:03

FDA Draft Guidance on MRD End Points in Myeloma Trials

6 months ago

Malin Hultcrantz, MD, PhD

0:41

Overused Buzzwords in Hematology and Oncology

6 months ago

Riley Kandel

0:31

Tackling Lifileucel in Metastatic Melanoma and Other Topics at TCT 2026

6 months ago

Amrita Desai, MD, MPH

0:37

Hematologic Oncologists Share Conference Must-Haves

6 months ago

Riley Kandel

0:34

Zanidatamab-Based Regimens Could Be A ‘Game Changer’ for First-Line HER2+ GEA Paradigm

6 months ago

Raji Shameem, MD

1:40

TCT 2026: CAR T-Cell Therapy Expert Insights

6 months ago

Ashling Wahner

Philippos Costa, MD, and Hari Deshpande, MD

0:2.02

International Chondrosarcoma Awareness Day: Targeted Therapies Gain Ground in Rare Bone Cancer

6 months ago

Philippos Costa, MD(+1 more)

0:28

Previewing Loncastuximab Tesirine in Heavily Pretreated Patients With Diffuse Large B-Cell Lymphoma

6 months ago

Fernando Gibran-Nunes, MD

0:58

Prophylactic Dexamethasone Mitigating Neurotoxicity in Multiple Myeloma

6 months ago

Kenneth Jin Chang Lim, MBBS

1:24

The Role of Molecular and Genetic Testing in Ph+ Acute Lymphoblastic Leukemia

6 months ago

Nicholas J. Short, MD

1:05

5-Year Data Update from the Phase 2 ELARA Trial

6 months ago

Peter Riedell, MD

0:55

Tackling the Barriers to Cervical Cancer Screening

6 months ago

Robert Neff, MD

4:00

OncLive Recognizes World Cancer Day

6 months ago

Ronac Mamtani, MD, MSCE(+3 more)

0:43

Unpacking OS Data from the ROSELLA Trial

6 months ago

Alexander B. Olawaiye, MD

Justin Call, MD, and D. Ross Camidge, MD, PhD

2:11

How I Discovered My True Calling in Oncology

6 months ago

Ross Camidge, MD, PhD(+1 more)

1:43

Optimizing HPV Vaccination for Cancer Prevention

6 months ago

Maurie Markman, MD

1:49

Implications of FDA Draft Guidance on MRD End Points in Myeloma Trials

6 months ago

Rahul Banerjee, MD

0:21

Outlining the Results of the HER2CLIMB-05 Trial in HER2+ Breast Cancer

6 months ago

Erika P. Hamilton, MD

0:54

Increasing Clinical Trial Access in Gynecologic Oncology

6 months ago

Katherine Kurnit, MD, MPH

1:25

Highlighting the Importance of the Bionic Breast Program

6 months ago

Stacy Tessler Lindau, MD, MA

0:38

The Role of Clinical Trials in Gynecologic Oncology

6 months ago

John Moroney, MD

1:22

Expert Insight on AI in Oncology and Clinical Trials at University of Chicago Comprehensive Cancer Center

6 months ago

Riley Kandel

1:18

Examining the Future of Bispecifics and CAR T-Cell Therapy in Lymphoma

6 months ago

Alexandra Rojek, MD

Molecularly Driven Therapies Drive Ongoing Research in MPNs

1:48

Molecularly Driven Therapies Highlight Ongoing Research in MPNs

6 months ago

John O. Mascarenhas, MD

1:06

Addressing the Need for Cancer Screening in Young Adults

6 months ago

Sonali M. Smith, MD

1:16

Unpacking the Future of AI in Oncology

6 months ago

Alexander T. Pearson, MD, PhD

1:22

MRD as a Surrogate End Point in Multiple Myeloma Trials

6 months ago

Marc J. Braunstein, MD, PhD

0:1.44

How HPV Testing Can Fall Through the Cracks in Cervical Cancer

6 months ago

Dana Chase, MD

2:06

FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

6 months ago

David A. Braun, MD, PhD

Video Shorts

Trending on OncLive

FDA Approves Rituximab Biosimilar for Hematologic Malignancies

Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC

Talk of Cure, a New ADC, and a Negative Trial: Breaking Down the Biggest Gynecologic Cancer News From ASCO 2026

Emerging Maintenance Strategies May be the Key to Extending Survival in ES-SCLC

Phase 1 Data Set the Stage for Further Exploration of Cevostamab in R/R Myeloma